Bioniche Animal Health was formed in 1979 as a privately owned company to develop vaccines and other pharmaceutical-based products for the preventative health management of animal diseases. Now a Division of the Bioniche Life Sciences Inc., a public company (TSX: BNC), Bioniche Animal Health has marketing subsidiaries in Australia, Canada, Europe, and the United States.
It is responsible for research, development, manufacturing, and marketing of veterinary biopharmaceutical products worldwide. The Division has a portfolio of products centered around five platform technologies in the broad categories of reproduction and embryo transfer; immunostimulants; and vaccines. Close liaisons have been established with a number of universities active in medical and veterinary research. These liaisons support and strengthen the research and development program, which is primarily focused on reducing the reliance on antibiotics in animal health care and on enhancing reproductive performance in animals.